Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 462 (LINC00462)
- Target
- LINC00462
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense lncRNA gene, Other
01
Overview
Long intergenic non-protein coding RNA 462 (LINC00462) is a long non-coding RNA gene located on chromosome 13, transcribed as an antisense lncRNA. It is not translated into protein. LINC00462 acts as a critical regulator in cancer biology, particularly pancreatic cancer and hepatocellular carcinoma, where its expression is often upregulated. Mechanistically, LINC00462 promotes cell proliferation, inhibits apoptosis, and drives EMT and metastasis. It functions as a competing endogenous RNA, modulating miRNA activity (especially miR-665) and influencing downstream signaling pathways such as TGFBR1/TGFBR2/SMAD2/3. LINC00462 serves as a promising biomarker for tumor aggressiveness and progression, though it is not currently targeted by any specific drugs.
- Other names
- LINC00462 (HGNC official symbol)long intergenic non-protein coding RNA 462 (full name)RP11-165D7.4 (Ensembl/other transcript alias)linc00462
02
Mechanism of action
no drugs currently target LINC00462 directly or via specific mechanisms
03
Biological functions
Regulation of cell cycleInhibition of apoptosis (cell death)Promotion of cell proliferationEpithelial-mesenchymal transition (EMT)Regulation of gene expression via miRNA spongingTumor growth and metastasisMay function as a competing endogenous RNA (ceRNA), modulating mRNA stability and translation indirectly
04
Disease associations
CancerPancreatic cancerHepatocellular carcinoma
05
Safety considerations
Therapeutic challenges of targeting lncRNAs: Off-target effects, potential broad consequences due to involvement in regulatory networks, and delivery challenges are general concerns for RNA-based therapeutics, but nothing unusually specific to LINC00462 beyond this has been reportedNo specific LINC00462-related toxicity reported; safety concerns are generic for lncRNA targeting
06
Biomarkers
High expression of LINC00462 in tumor tissue (pancreatic cancer, hepatocellular carcinoma) correlates with poor differentiation, larger tumor size, advanced TNM stage, and distant metastasis, suggesting its use as a prognostic biomarkerNo predictive biomarkers for therapy selection are currently established.
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 462 (LINC00462).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 462 (LINC00462).